InMed Pharmaceuticals (INM) Net Income Growth (3y) (2024 - 2026)
InMed Pharmaceuticals (INM) Net Income Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -27.09% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - | -14.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.61% |
| Dec 31, 2025 | 1.12% |
| Sep 30, 2025 | 21.06% |
| Jun 30, 2025 | 45.04% |
| Mar 31, 2025 | 75.07% |
| Dec 31, 2024 | 15.60% |
| Sep 30, 2024 | 17.35% |